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Patient Characteristics
Characteristics n (%)
Total patients 86(100)
Age, yrs
Less than 50 48(56)
More than 50 38(44)
Diagnosis
AML 34(39)
ALL 10(12)
MDS 16(19)
NHL/HD 8(9)
Others 18(21)
Graft source
Bone marrow 6(7)
Peripheral blood stem cells 80(93)
Conditioning
MA 55(64)
RIC 31(36)
GVHD prophylaxis
CSA/Campath 49(57)
CSA/MMF 33(38)
Others 4(5)338
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Results of children acute lymphoblastic leukemia (ALL)
therapy improved dramatically in the past decades. Patients
with very high risk leukemia may beneﬁt from allogeneic
hematopoieic stem cell transplantation (HSCT) after mye-
loablative conditioning regimen with expected overall
survival of 70%. However such therapy could induce high
toxicity such as acute kidney injury (AKI). In literature, up to
45% of children may experiment acute renal failure during
HSCT. It could increase other toxicities and often leads to
chronic kidney disease.
In this study we retrospectively reviewed medical ﬁles of
patients treated at Robert Debré Hospital in Paris for very
high risk ALL by allogenetic HSCT.
From March 2007 to January 2012, 57 consecutive
patients were included. All patients received a myeloablative
conditioning regimen followed by HSCT from either related
or unrelated 9 and 10/10 HLA compatible donor or 4 to 6/6
cord blood. Patients received TBI in 6 fractions in 3 days from
D-6 to D-3 and then etoposide (60mg/kg) at D-2 in 4 hour-
infusion in central venous line. GvHD prophylaxis was
cyclosporine A (CSA) 1.5mg/kg twice a day in 2-hour infusion
alone for patients transplanted with sibling donor and CSA +
short-course methotrexate and ATG for others.
From the 57 patients, seven patients (14%) developed AKI
at day +1 from etoposid infusion (AKI group), deﬁned by an
increase of creatinine level of more than 2 fold of their own
creatinine basis level and estimated glomerular ﬁltration rate
(EGFR) less than 90 ml/min/1.73m2 the day after etoposide
injection. Another group of 10 patients (17.5%) had
a subclinical AKI with an increase between 1.5 and 2 fold
(sAKI group). EGFR means before graft of the whole cohort
was of 185.7ml/min/1.73m2 [170-200]. At day +1 from eto-
poside infusion, AKI groupe patients eGFR mean was of 55.4
[33-79] (P < .0001) and 95.5 [72-118] (P < .0155) ml/min/
1.73m2respectively. Secondary to acute kidney injury, ﬁve
patients among seven required a delay for stem cell injection.
Two years overall survival at was of 84.4% [76.8-98] and was
not statistically different between control, AKI and sAKI
group. Relapse was similar in all groups (18.6% [42-3.8] for all
patients). Transplanted related mortality was higher in AKI
and sAKI groups versus control group. Indeed 3/17 patients
with persistent complete remission died in those 2 groups
(TRM of 17.6% [0.4-50.6]), while no patient died in control
group (P ¼ .007). Finally, GVH was of 62.8% [49.7;73.4] in
control group, 85.7% [94.1;67.6] in AKI group and 80.6
[92.6;54.6] in sAKI group (p ¼NS).
Acute renal injury is frequent with TBI-VP16 based condi-
tioning regimen for high risk ALL and occurs about 24 hours
afteretoposide injection. It isamajoradverseeffect,may impact
mortality and delay transplantation. Long term consequenceand chronic kidney disease should be evaluated among survi-
vors. Further study are needed to specify these results.339
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Introduction: Invasive fungal infections (IFI) contribute to
morbidity and mortality of hematopoietic cell trans-
plantation (HCT). We evaluated micafungin followed by
posaconazole for primary IFI prophylaxis.
Methods: Consecutive patients who received unrelated HCT
at PMH from July 2009 to Dec 2011 with antifungal
prophylaxis of Micafungin (50 mg IV daily) during hospital-
ization followed by posaconazole (200 mg po tid) for three
months were reviewed.
Results: 86 patients received HCT in above setting. Median
age was 48.3(range 18.6-71.2) years. 71 were 10/10 matches
(allele level) while 15 were 9/10 (allele or antigen mismatch)
(Table 1).
72 (83.7%) developed acute GVHD (aGVHD). Median day
of development of aGVHD was 28.5 (range 7-100) days.
Overall 1 and 2 year survival were 81.2% and 64.1% respec-
tively. Relapse rate was 11.63%.
Median day of start of posaconazole was 22.5 (range
14-64) days. All patients tolerated posaconazole and mica-
fungin well.
3 (3.5%) of patients were diagnosed with IFI in ﬁrst three
months. Median day of diagnosis was 13(range11-81) days.
Diagnosis was based on symptoms with abnormal imaging
and BAL galactomannan positivity in one. Two cases were
treated for symptoms with imaging abnormalities (Table 2).
All patients were switched to voriconazole and improved
which makes it less likely that they were IFI.
